4
Changes in Ownership
Atea Pharmaceuticals, Inc. Filed Acc 0000950170-24-010967
Chief Development Officer sold 14,029 shares at $3.84 ($53,913)
- Chief Development Officer acquired 46,800 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Hammond Janet MJ Chief Development Officer | 2024-01-31 | Option exercise | +46,800 | 49,391 | D | ||
| Hammond Janet MJ Chief Development Officer | 2024-02-01 | Sale | −14,029 | $3.84 | $53,913 | 35,362 | D |
| Derivatives | |||||||
| Hammond Janet MJ Chief Development Officer | 2024-01-31 | Option exercise · Restricted Stock Units | −46,800 | 93,600 | D | ||
| Hammond Janet MJ Chief Development Officer | 2024-01-31 | Grant or award · Stock Option (Right to Buy) | +225,200 | 225,200 | D | ||
| Open-market sales · 14,029 sh · avg $3.84 · $53,913 | |||||||
Loading xslF345X05/ownership.xml…